Breaking News

Financial Report: AbbVie

October 25, 2013

Humira sales up 19% in the quarter


3Q Revenues: $4.7 billion (+3%)

3Q Earnings: $964 million (-39%)

YTD Revenues: $13.7 billion (+4%)

YTD Earnings: $3.0 billion (-20%)

Comments: Humira sales were $2.8 billion in the quarter, up 19%. AndroGel and Kaletra sales were down 11% to $248 million and $237 million, respectively. Niaspan sales were down 13% to $201 million. TriCor/Trilipix sales were down 88% to $39 million, due to loss of exclusivity. Synthroid sales were up 23% to $161 million. Creon and Zemplar sales were up 10% to $101 million and $100 million, respectively. R&D expenses were down 12% to $714 million.
blog comments powered by Disqus
  • Quality Risk Management

    Quality Risk Management

    Cheryl Abernathy and Bryan Sasbon, Quality Assurance Operations Manager, Ropack Pharma Solutions; QA Director & Regulatory Affairs, Ropack Pharma Solutions||September 8, 2016
    Embracing the process as a means to a strong quality culture

  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments